Sai Parenterals Limited has informed the Exchange about Transcript
SAIPARENT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sai Parenterals, a newly listed pharma company post-IPO, reported FY26 consolidated revenue of INR381 crore (133% growth) following the November 2025 acquisition of Australian-based Noumed Pharmaceuticals. Standalone FY26 revenue was INR162 crore with 21% EBITDA margin. Management guided FY27 revenue target of INR750 crore with 17% EBITDA margin, noting FY27 will be an investment year as the INR440 crore capex program (INR110 crore for Indian EU-GMP upgrades, INR15 crore for R&D, AUD 53 million for Australian facility) completes by Q4 FY27. The company expects FY28 to be the year when all capex projects become operational and drive margin expansion through vertical integration—shifting Noumed's outsourced manufacturing to internal Sai facilities. CFO confirmed FY27 will be peak debt year with debt declining from FY28 onwards.
Management's margin guidance improvement to 17% EBITDA in FY27, driven by vertical integration benefits and operational leverage from upcoming capex, signals positive earnings trajectory for shareholders. The company also disclosed a strong order pipeline of 67 dossiers under development for commercialization in FY27-28.